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EDITORIAL

Anemia of Chronic Kidney Disease: Forward
to the Past

T

his issue of Advances in Chronic Kidney Disease limits the broad topic of the anemia of
chronic kidney disease (CKD) to 2 issues: (1)
the reemergence of iron as a principal hematinic and (2) the clinical outcomes associated
with iron use in CKD, the biological and practice-related causes of hyporesponsiveness
and hemoglobin variability, the relationship
between hemoglobin targets and erythropoiesis-stimulating agents (ESAs), and the future
of anemia management in the United States,
which may involve a host of new iron-containing ESAs.
Phylacus, through the advice of Melampus
the seer, cured his son Iphiclus of impotence
by having him ingest iron melted from his
broadsword. Despite the mythology of this
original report of oral iron therapy, this element, for decades, remained the sole treatment
for the anemia of chronic kidney disease. When
iron therapy failed to elevate hemoglobin
levels in end-stage renal disease (ESRD) patients, blood transfusion therapy was the only
recourse for those individuals with obligate
blood losses from the dialytic procedures and
multiple venipunctures. Thus, survival for dialysis patients was perforce associated with
the risk of transfusion-related hemosiderosis
and/or hemachromatosis. The putative consequence of maintaining hemoglobin levels .6.5
to 7 g/dL, which today are considered suboptimal by any standard, were iron overload,
manifested as hyperferritinemia, and, possibly,
increased cardiovascular risk.
The ‘‘iron hypothesis’’—cardiac dysfunction
induced by iron overload—first posited by Sullivan in 1981 noted that males, in age-dependent

fashion, accumulate more iron than females.
However, the actual thesis of Sullivan was not
that cardiovascular disease accrued from iron
overload but that iron deficiency might be protective against atherosclerosis. Extending this
tenet, iron, as participant in Haber-Weiss– and
Fenton-type reactions might inure oxidative
stress, aggravating preexisting atherosclerotic
lesions. Whether these circumstances played
out in an individual patient could not be
precisely assayed, and before and even after
the introduction of recombinant human erythropoietin, iron therapy in ESRD patients was approached with tremendous caution by some
and not at all by others.
In ESRD patients, the erythropoietic response to oral iron preparations was variable,
with clinician–scientists reporting either no or
positive increments of hemoglobin after the
institution of iron. In non–dialysis-dependent
CKD patients, the hemoglobin response in
controlled, clinical trials was often better,
and in some instances oral treatment equaled
intravenous therapy, albeit less rapidly. However, the nonresponsiveness of some patients
continued to vex nephrologists; ‘‘Why did
some patients respond so vigorously to seemingly small amounts of erythropoietic peptide
treatment, whereas others were seemingly
resistant to any dose?’’
Barriers to response from ESAs were attributed to a seeming pastiche of factors. Aside
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from the usual suspects of blood loss, relative
endogenous erythropoietin deficiency and
absolute or functional iron deficiency, the etiologies of hyporesponsiveness included the
following: vitamin deficiencies, malnutrition,
aluminum toxicity, inadequacy of dialysis,
and the then-unformulated concept(s) of
inflammation and its attendant biomarkers,
among others. Driven by quality of life data
and observational trials that supported normal or near-normal hemoglobin levels, ESA
doses were escalated. Using hemoglobin as
the metric, a ‘‘one size (of hemoglobin) fits
all’’ approach was adopted by many practitioners, and, in ESRD patients, ESA doses
were escalated without a ‘‘stopping level’’
until the Centers for Medicare and Medicaid
Services imposed upper limits for them. However, although the concept of erythropoietin
sensitivity had already been conceived and
modeled, it never achieved universal, practice-based status. Thus, patients with lower
sensitivity to ESAs were persistently treated
toward mean target (and nonachievable) hemoglobin levels, and institutional protocols
to drive hemoglobin levels upward remained
intact and profitable.
Within the last few years, several randomized, controlled trials have sharpened the
focus of iron (Dialysis Patients’ Response
to Intravenous Iron With Elevated Ferritin
[DRIVE] Trials I and II) and ESA (Correction
of Hemoglobin and Outcomes in Renal Insufficiency [CHOIR] and the Cardiovascular
Risk Reduction by Early Anemia Treatment
with Epoetin Beta [CREATE] trials) management in CKD. Collectively, these trials have
reinforced the notion that increasing transferrin saturation in CKD and ESRD patients by
parenteral iron treatment induces an ESAsparing effect and that complete correction
of hemoglobin in non–dialysis-dependent
and dialysis-dependent CKD is not necessary, with potential harm occurring when attempting to do so en masse. However, the
recent ‘‘landmark’’ analysis by Szczech et al
suggests that it is ‘‘the means’’ by which one
arrives at the target hemoglobin rather than
the target itself that is of greatest relevance.
A patient with high ESA sensitivity and
who easily attains a target hemoglobin value of 12 g/dL should not be considered

equivalent to one who has an ESA-resistant
state. Remarkably, we rediscovered the
observations of Eschbach et al that described
disproportionately high erythropoietin alfa
administration in a relatively small fraction
of patients in their landmark clinical trial
of epoetin alfa use in ESRD date back to
1989. Similarly notable is the observation,
by the same investigators, that the epoetintreated cohort in their trial had a mean
ferritin level of approximately 1,500 ng/mL
at study initiation, and they subsequently
decreased as hemoglobin levels increased
significantly.
Advances in molecular biology have substantially improved our understanding of the
anemias of chronic disease. The anemia of
CKD is among them, with the added burden
of erythropoietin deficiency. Recent elucidations of specifically disrupted points of erythroid marrow function by inflammatory
mediators, especially proinflammatory cytokines and inflammation-mediated induction
of hepcidin have improved our understanding
of ESA hyporesponsiveness. These observations and those of the non-erythroid-related
effects of ESAs, coupled with clinical data, contribute to a simplified (but not simple) treatment model for anemic CKD patients: (1) rule
out occult blood loss, (2) eliminate all sources
of inflammation and prescribe adequate iron
and ESA doses afterward, (3) determine the
level of ESA responsiveness, and (4) adjust
ESA dosing based within limits based on the
level of ESA responsivenes.
New hemoglobin targets and iron parameters have been recommended by multiple authorities. Recently, regulatory/payer agencies
have capitated ESA dosing. Iron treatment in every CKD must always be considered, and iron
therapy must be integrated into any protocol
of anemia management and consider essential
as we had in the pre-ESA era. By looking ‘‘forward to the past,’’ we will maintain judicious
use of iron and ESA therapy, which only serves
to benefit patients in the biologic sense and the
health care society in an economic sense.
Perhaps, we should reflect on the words of
physician–philosopher, William James: ‘‘When
a thing is new, people say: ‘It is not true.’ Later,
when its truth becomes obvious, they say: ‘It’s
not important.’ Finally, when its importance
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cannot be denied, they say ‘Anyway, it’s not
new.’’’ We should heed the advice of our parents: ‘‘Everything in moderation.nothing in
excess.’’
Nephrologists managing patients with the
anemia of CKD must continually strive for
superior outcomes in their patient populations. When properly written, protocolized
management of anemia can facilitate efficient
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delivery of care and drive improved outcomes
in a safe manner. When used properly, the
same protocols can identify those patients
who, after scrupulous elimination of causes
of suboptimal erythropoiesis, harbor true
ESA-resistant states and require individualized therapy.
Jerry Yee, MD
Editor

